JAMA Oncology

12/12/2025

From JAMA: Breast cancer is the most common malignancy in women and optimizing screening is essential for early detection and reducing harm.

In the WISDOM randomized clinical trial, researchers assessed outcomes of risk-based screening vs annual mammography in more than 28 000 US women aged 40 to 74 years without prior breast cancer. Risk-based screening used genetic testing, polygenic risk score, and clinical risk models to stratify recommendations from delayed screening, to biennial, annual, or alternating mammography and MRI.

While the study found risk-based screening was noninferior for detection of stage ≥IIB compared with annual screening, rates of breast biopsies did not decrease overall with risk-based screening.



https://ja.ma/48xc716

12/12/2025

Definitive radiotherapy with or without chemotherapy in anterior nasal cavity cancers achieved high rates of long-term organ preservation and favorable local recurrence rates for patients who declined rhinectomy or had unresectable disease. https://ja.ma/4pz8RZf

12/11/2025

In this secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with greater and more persistent self-reported cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women with . https://ja.ma/4iOl2i4

12/11/2025

In this secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with greater and more persistent self-reported cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women with . https://ja.ma/4rRvKsj

12/11/2025

💬 Editorial: Cancer-related cognitive impairment frequently affects survivors and may persist for years after treatment, with greater risk among those receiving chemoendocrine therapy.

https://ja.ma/4p6Oba1

12/06/2025

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events, supporting 600 mg as the standard dose with reduction to manage toxicity. https://ja.ma/44E0RNW

12/05/2025

Patients with muscle-invasive bladder cancer may undergo a surgery called radical cystectomy (removal of the bladder). Once the bladder is removed, the body needs a new way to pass urine, which is called a urinary diversion.

This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life. https://ja.ma/3Y9bKng

12/05/2025

A prediction model incorporating clonal hematopoiesis and other factors identified substantial heterogeneity in the cancer-preventive effect of low-dose aspirin among older adults.

This secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial explores whether individual characteristics are associated with estimated treatment effects of low-dose aspirin on 5-year cancer incidence in healthy older adults.

12/04/2025

💬 Editorial: Precision adjuvant therapy for stage III may be enhanced through molecular profiling for ctDNA status and PIK3CA mutation, informing use of celecoxib or aspirin alongside standard treatment. https://ja.ma/3Kw5FhF

12/04/2025

ctDNA status may help identify which patients benefit from adjuvant celecoxib, supporting personalized treatment approaches in . https://ja.ma/48A59Hp

12/03/2025

Many elevated PSA levels normalize within a year, but consistently high values warrant direct diagnostic evaluation without repeated testing. https://ja.ma/3M0Ladj

12/02/2025

Among adolescents and young adults with , 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).

https://ja.ma/4ohz78M